CymaBay Chief Medical Officer Boudes to Depart at September’s End

CymaBay Therapeutics (NASDAQ: [[ticker:CBAY]]) announced that Pol Boudes, the company’s chief medical officer since 2014, will step down at the end of the month. No reason for Boudes’s departure was given, but CymaBay said in a regulatory filing that the decision was mutual. A search for a successor is underway.

Newark, CA-based CymaBay is developing drugs to treat liver diseases. In June, the company reported that seladelpar, its experimental treatment for nonalcoholic steatohepatitis, did not beat a placebo in early results from a Phase 2 clinical trial. But the company said that the study would continue in hopes of producing better data.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan